A novel drug (pridopidine) that stabilises dopamine signalling in areas of the brain that control movement and coordination, appears well tolerated and warrants further study in patients with Huntington's disease (HD), a ...
Nov 7, 2011
0
0
Uncontrolled high blood pressure damages the brain's structure and function as early as young middle-age, and even the brains of middle-aged people who clinically would not be considered to have hypertension have evidence ...
Oct 31, 2012
0
0
A new kind of antipsychotic has been found to relieve terrifying and disturbing symptoms suffered by millions of people with Alzheimer's disease worldwide.
Feb 13, 2018
0
95
Researchers from the University of Florida and 14 additional medical centers reported results today in the online version of The Lancet Neurology journal indicating that deep brain stimulation — also known as DBS — ...
Jan 11, 2012
0
0
Over half of all Alzheimer's disease cases could potentially be prevented through lifestyle changes and treatment or prevention of chronic medical conditions, according to a study led by Deborah Barnes, PhD, a mental health ...
Jul 19, 2011
0
0
Intensive control of blood sugar levels beyond standard targets provides no additional protection against cognitive decline in older people with diabetes than standard treatment, according to a national study coordinated ...
Sep 27, 2011
0
0
The Lancet Neurology has published data from the phase 3 MycarinG study evaluating the efficacy and safety of rozanolixizumab in adult patients with acetylcholine receptor autoantibody-positive (AChR-Ab+) or muscle-specific ...
Apr 13, 2023
0
21
Treating "brain tsunamis” or "killer waves” could stop many victims of major head injury from suffering additional brain damage, a study published in Lancet Neurology has found.
Dec 7, 2011
0
0
New research published Online First in The Lancet Neurology, has found that epilepsy patients who receive additional treatment with antiepileptic drugs (AEDs) have about a seven times lower risk of dying from a sudden unexpected ...
Sep 18, 2011
0
0
Argenx, a Belgium pharmaceutical company, recently announced that The Lancet Neurology has published pivotal trial results from the Phase 3 ADAPT trial of efgartigimod, an FcRn antagonist, for the treatment of adults living ...
Jun 18, 2021
0
3
